Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ANASTROZOLE/PD:

Search results

Items: 1 to 20 of 26

1.

Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only.

Sedloev T, Vlahova A, Usheva S, Vasileva-Slaveva M, Spiridonova T, Spirdonov J.

Anticancer Res. 2019 Aug;39(8):4393-4398. doi: 10.21873/anticanres.13609.

PMID:
31366535
2.

Temperature/pH-Triggered PNIPAM-Based Smart Nanogel System Loaded With Anastrozole Delivery for Application in Cancer Chemotherapy.

Singh A, Vaishagya K, K Verma R, Shukla R.

AAPS PharmSciTech. 2019 Jun 4;20(5):213. doi: 10.1208/s12249-019-1410-3.

PMID:
31165298
3.

Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.

Tenti S, Giordano N, Cutolo M, Giannini F, Fioravanti A.

Medicine (Baltimore). 2019 Mar;98(13):e15052. doi: 10.1097/MD.0000000000015052. Review.

4.

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.

Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HH, Livingston RB, Hortobagyi GN.

N Engl J Med. 2019 Mar 28;380(13):1226-1234. doi: 10.1056/NEJMoa1811714. Erratum in: N Engl J Med. 2019 Jun 6;380(23):2282.

PMID:
30917258
5.

Idiopathic gonadotropin-independent precocious puberty - is regular surveillance required?

Arya VB, Davies JH.

J Pediatr Endocrinol Metab. 2019 Apr 24;32(4):403-407. doi: 10.1515/jpem-2018-0419.

PMID:
30849047
6.

Preparation and in vitro/in vivo evaluation of anastrozole reservoir-type intravaginal ring.

Xia L, Qiu S, Liu Z, Ning M.

Biomed Chromatogr. 2019 Apr;33(4):e4459. doi: 10.1002/bmc.4459. Epub 2019 Jan 21.

PMID:
30536439
7.

Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation.

Regenthal R, Voskanian M, Baumann F, Teichert J, Brätter C, Aigner A, Abraham G.

Drug Des Devel Ther. 2018 Nov 1;12:3653-3664. doi: 10.2147/DDDT.S170764. eCollection 2018.

8.

Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.

Kamaraju S, Shi Y, Smith E, Nattinger AB, Laud P, Neuner J.

Clin Cardiol. 2019 Jan;42(1):93-100. doi: 10.1002/clc.23114. Epub 2018 Dec 7.

9.

Effects of psoralen on the pharmacokinetics of anastrozole in rats.

Zhang Y, Wu J, Zhou Y, Yin Y, Chen H.

Pharm Biol. 2018 Dec;56(1):433-439. doi: 10.1080/13880209.2018.1501584.

10.

Bone health consequence of adjuvant Anastrozole in monotherapy or associated with biochanin-A in ovariectomized rat model.

Mohamed AA, Ahmed MM, Gomaa M, Ebraheim LLM.

Life Sci. 2018 Nov 1;212:159-167. doi: 10.1016/j.lfs.2018.09.059. Epub 2018 Oct 2.

PMID:
30290186
11.

Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).

Kim JY, Im SA, Jung KH, Ro J, Sohn J, Kim JH, Park YH, Kim TY, Kim SB, Lee KS, Kim GM, Kim SH, Kim S, Ahn JS, Lee KH, Ahn JH, Park IH, Im YH; breast cancer committee of Korean Cancer Study Group (KCSG).

Eur J Cancer. 2018 Nov;103:127-136. doi: 10.1016/j.ejca.2018.08.004. Epub 2018 Sep 14.

PMID:
30223226
12.

Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature.

Partl R, Regitnig P, Tauber G, Pötscher M, Bjelic-Radisic V, Kapp KS.

Strahlenther Onkol. 2018 Nov;194(11):1060-1065. doi: 10.1007/s00066-018-1336-9. Epub 2018 Jul 16.

13.

Combination therapy with clomiphene citrate and anastrozole is a safe and effective alternative for hypoandrogenic subfertile men.

Alder NJ, Keihani S, Stoddard GJ, Myers JB, Hotaling JM.

BJU Int. 2018 Oct;122(4):688-694. doi: 10.1111/bju.14390. Epub 2018 Jun 6.

PMID:
29873446
14.

Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer.

Bender CM, Merriman JD, Sereika SM, Gentry AL, Casillo FE, Koleck TA, Rosenzweig MQ, Brufsky AM, McAuliffe P, Zhu Y, Conley YP.

Oncol Nurs Forum. 2018 May 1;45(3):308-326. doi: 10.1188/18.ONF.308-326.

15.

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J.

J Clin Oncol. 2018 Jul 1;36(19):1941-1948. doi: 10.1200/JCO.2017.76.4258. Epub 2018 Apr 20.

16.

Erythematous Maculopapular Eruption Induced by Anastrozole: The First Case.

Cozzani E, Trave I, Burlando M, Parodi A.

Am J Ther. 2018 Nov/Dec;25(6):e743-e744. doi: 10.1097/MJT.0000000000000755. No abstract available.

PMID:
29668491
17.

In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.

Bozkaya Y, Erdem GU, Demirci NS.

J Oncol Pharm Pract. 2019 Apr;25(3):754-757. doi: 10.1177/1078155218762626. Epub 2018 Mar 14. Review.

PMID:
29536789
18.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.

Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29482983
19.

Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).

Nakayama T, Sagara Y, Takashima T, Matsunami N, Masuda N, Miyoshi Y, Taguchi T, Aono T, Ito T, Kagimura T, Noguchi S.

Cancer Chemother Pharmacol. 2018 Apr;81(4):755-762. doi: 10.1007/s00280-018-3544-5. Epub 2018 Feb 21.

20.

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).

Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D.

Breast Cancer Res Treat. 2018 Jun;169(3):537-548. doi: 10.1007/s10549-018-4713-2. Epub 2018 Feb 17.

Supplemental Content

Loading ...
Support Center